Why It Matters

Bavarian Nordic faces a political environment where HHS leadership is slashing mRNA vaccine funding while the broader vaccine sector faces unprecedented skepticism. Yet the company’s traditional, non-mRNA smallpox and mpox vaccines position it to benefit from bipartisan support for domestic manufacturing resilience and biodefense preparedness—separate from the politically charged vaccine skepticism consuming Washington.

The real risk is uncertainty around PAHPA reauthorization and BARDA funding, which directly underpin the government contracts essential to Bavarian Nordic’s business model.

By the Numbers

Bavarian Nordic Inc. spent $130,000 on lobbying in the last quarter of 2025, continuing its consistent quarterly spending pattern throughout 2024 and 2025.

The company is a longstanding lobbying player, maintaining continuous presence since 2006 with 152 total disclosures exceeding $12.7 million. Laura Lisa Efros, the sole in-house lobbyist, has worked exclusively for Bavarian Nordic since April 2019, handling 29 disclosures valued at $3.64 million.

The Agenda

Bavarian Nordic Inc. is lobbying on vaccine development, biodefense, and pandemic preparedness funding. The Danish biotechnology company focused Q4 2025 efforts on securing federal support for its smallpox and mpox vaccines through several interconnected areas:

  • Biodefense and emergency preparedness funding, particularly through BARDA
  • Government appropriations for Labor-HHS-ED and National Defense Authorization Act
  • Pandemic preparedness legislation, including PAHPA reauthorization and the MedShield Act of 2025
  • Vaccine development and manufacturing policy, emphasizing domestic production and supply chain resilience

Broader Context

Bavarian Nordic’s last quarter
lobbying occurs amid a dramatically shifted federal vaccine landscape. HHS Secretary Robert F. Kennedy Jr. announced a wind-down of nearly $500 million in mRNA vaccine development funding in August 2025, creating uncertainty across the vaccine sector. However, this may create opportunities for Bavarian Nordic, whose flagship products use traditional platforms rather than mRNA technology.

The most critical near-term threat is PAHPA, operating under temporary extensions since September 2023. PAHPA encompasses BARDA, which directly funds vaccine development and procurement. Over 100 organizations have called for comprehensive reauthorization, but legislative action has stalled.

Meanwhile, the bipartisan MedShield Act of 2025 would allocate $300 million for accelerated vaccine development, aligning with congressional goals for domestic pharmaceutical manufacturing.

Between The Lines

Congressional action on pandemic preparedness remains fragmented, creating both risks and opportunities. While Democratic senators have criticized Kennedy’s "reckless" vaccine funding cuts, Republican support for the reductions highlights deep partisan divisions.

This volatility may benefit Bavarian Nordic’s positioning. The company can frame its biodefense vaccines as national security priorities separate from broader vaccine skepticism, finding bipartisan common ground on pandemic preparedness and domestic manufacturing resilience.

Competitive Landscape

The federal government’s dramatic vaccine funding shifts create a fragmented competitive environment. Kennedy’s decision to wind down mRNA development disrupted programs at major pharmaceutical companies including Pfizer, Moderna, and Sanofi Pasteur, potentially giving Bavarian Nordic’s non-mRNA platform relative advantage.

Congressional demand for domestic pharmaceutical manufacturing strengthens competition around government contracts and BARDA funding, with multiple companies likely pursuing new opportunities under the MedShield Act.

The Bottom Line

Bavarian Nordic Inc. continues its nineteen-year effort to secure federal biodefense funding, spending $130,000 in the last quarter. While the MedShield Act offers new funding opportunities and the company’s non-mRNA platform positions it favorably amid HHS cuts, the uncertain fate of PAHPA reauthorization poses significant risks to its government-dependent business model.

Access the Legis1 platform for comprehensive political news, data, and insights.